XenoLung Seeks to increase access to and improve outcomes after lung transplantation for people with PAH and other fatal lung diseases. The promise of lung transplantation as an effective therapy for PAH and other fatal lung diseases is widely accepted. Recipients of successful lung transplants have the potential to experience improved quality of life and survival. However, access to lung transplantation for patients in need remains limited by the severe shortage of suitable donor lungs. Transplant recipients face many challenges including the life-long need to take powerful immunosuppressive medications to prevent organ rejection.